Manufacturer's PIL, Levocarnitine Paediatric 30% Oral Solution
$7.99 Golden Pearl Skin Polishing Kit Polish & Refine
Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
This depends on: Body weight Type of injury or condition Goals (e.g., recovery vs performance enhancement) Some users split the dose into morning and evening shots for sustained effect
Carbohydrates will provide energy and fiber to help with blood sugar control, better digestion, and a balanced mood
The combination of PIO with GLP-1R agonists also demonstrated significant reductions of hepatic fat content, liver indices, as well as markers of inflammation and fibrosis (Table I)
